Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials | Zendy

Álvaro H. Borges | Zendy; Andreas Lundh | Zendy; Britta Tendal | Zendy; John Bartlett | Zendy; Nathan Clumeck | Zendy; Dominique Costagliola | Zendy; Eric S. Daar | Zendy; Patricia Echeverría | Zendy; Magnus Gisslén | Zendy; Tania B. HuedoMedina | Zendy; Michael D. Hughes | Zendy; Katherine Huppler Hullsiek | Zendy; Paul Khabo | Zendy; Stephanus Komati | Zendy; Princy Kumar | Zendy; Shahin Lockman | Zendy; Rodger D. MacArthur | Zendy; Franco Maggiolo | Zendy; Alberto Matteelli | Zendy; José M. Miró | Zendy; Shinichi Oka | Zendy; Kathy Petoumenos | Zendy; Rebekah Puls | Zendy; Sharon A. Riddler | Zendy; Paul E. Sax | Zendy; Juan SierraMadero | Zendy; Carlo Torti | Zendy; Jens Lundgren | Zendy

Open Access

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials

Author(s) -

Álvaro H. Borges,

Andreas Lundh,

Britta Tendal,

John Bartlett,

Nathan Clumeck,

Dominique Costagliola,

Eric S. Daar,

Patricia Echeverría,

Magnus Gisslén,

Tania B. HuedoMedina,

Michael D. Hughes,

Katherine Huppler Hullsiek,

Paul Khabo,

Stephanus Komati,

Princy Kumar,

Shahin Lockman,

Rodger D. MacArthur,

Franco Maggiolo,

Alberto Matteelli,

José M. Miró,

Shinichi Oka,

Kathy Petoumenos,

Rebekah Puls,

Sharon A. Riddler,

Paul E. Sax,

Juan SierraMadero,

Carlo Torti,

Jens Lundgren

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw236

Subject(s) - medicine , discontinuation , ritonavir , reverse transcriptase inhibitor , randomized controlled trial , confidence interval , protease inhibitor (pharmacology) , relative risk , gastroenterology , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy

Previous studies suggest that nonnucleoside reverse-transcriptase inhibitors (NNRTIs) cause faster virologic suppression, while ritonavir-boosted protease inhibitors (PI/r) recover more CD4 cells. However, individual trials have not been powered to compare clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research